EA199700413A1 - Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия - Google Patents

Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия

Info

Publication number
EA199700413A1
EA199700413A1 EA199700413A EA199700413A EA199700413A1 EA 199700413 A1 EA199700413 A1 EA 199700413A1 EA 199700413 A EA199700413 A EA 199700413A EA 199700413 A EA199700413 A EA 199700413A EA 199700413 A1 EA199700413 A1 EA 199700413A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccine
antigen
aluminum phosphate
polyacharide
composition containing
Prior art date
Application number
EA199700413A
Other languages
English (en)
Russian (ru)
Inventor
Жюльен Петерманс
Пьер Озе
Original Assignee
Смитклайн Бичам Байолоджикалз, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199700413(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en
Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en
Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en
Priority claimed from GBGB9606032.2A external-priority patent/GB9606032D0/en
Application filed by Смитклайн Бичам Байолоджикалз, С.А. filed Critical Смитклайн Бичам Байолоджикалз, С.А.
Publication of EA199700413A1 publication Critical patent/EA199700413A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA199700413A 1995-06-23 1996-06-19 Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия EA199700413A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9512827.8A GB9512827D0 (en) 1995-06-23 1995-06-23 Vaccines
GBGB9513443.3A GB9513443D0 (en) 1995-07-01 1995-07-01 Vaccines
GBGB9525657.4A GB9525657D0 (en) 1995-12-15 1995-12-15 Vaccines
GBGB9606032.2A GB9606032D0 (en) 1996-03-22 1996-03-22 Vaccines
PCT/EP1996/002690 WO1997000697A1 (en) 1995-06-23 1996-06-19 A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate

Publications (1)

Publication Number Publication Date
EA199700413A1 true EA199700413A1 (ru) 1998-08-27

Family

ID=27451299

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700413A EA199700413A1 (ru) 1995-06-23 1996-06-19 Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия

Country Status (35)

Country Link
EP (2) EP1082965B1 (enExample)
JP (2) JP4850987B2 (enExample)
KR (1) KR100425929B1 (enExample)
CN (1) CN1146444C (enExample)
AP (1) AP812A (enExample)
AR (1) AR003006A1 (enExample)
AT (2) ATE433329T1 (enExample)
AU (1) AU696338B2 (enExample)
BG (1) BG62720B1 (enExample)
BR (1) BRPI9609414B8 (enExample)
CA (1) CA2222455C (enExample)
CY (1) CY2297B1 (enExample)
CZ (1) CZ288908B6 (enExample)
DE (2) DE69612198T3 (enExample)
DK (2) DK1082965T3 (enExample)
DZ (1) DZ2055A1 (enExample)
EA (1) EA199700413A1 (enExample)
EG (1) EG25924A (enExample)
ES (2) ES2157447T5 (enExample)
GR (1) GR3036088T3 (enExample)
HU (1) HU224514B1 (enExample)
IL (1) IL122588A (enExample)
MA (1) MA23918A1 (enExample)
MY (1) MY114786A (enExample)
NO (1) NO325169B1 (enExample)
NZ (1) NZ312132A (enExample)
OA (1) OA10646A (enExample)
PE (1) PE11298A1 (enExample)
PL (1) PL184872B1 (enExample)
PT (2) PT1082965E (enExample)
SI (2) SI0833662T2 (enExample)
SK (1) SK176197A3 (enExample)
TR (1) TR199701682T1 (enExample)
TW (1) TW467746B (enExample)
WO (1) WO1997000697A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
US6468765B1 (en) 1995-04-21 2002-10-22 Human Genome Sciences, Inc. Selected Haemophilus influenzae Rd polynucleotides and polypeptides
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
IL122588A (en) * 1995-06-23 2001-12-23 Smithkline Beecham Biolog A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
CA2259415A1 (en) * 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
AU750587B2 (en) * 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
DK1296715T4 (en) * 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
PT2332581E (pt) 2001-01-23 2015-10-16 Sanofi Pasteur Inc Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
MXPA05004528A (es) 2002-11-01 2005-07-26 Glaxosmithkline Biolog Sa Composicion inmunogenica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2461350T3 (es) 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
ATE474595T1 (de) * 2003-10-02 2010-08-15 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
BRPI0610297A2 (pt) 2005-04-18 2010-06-08 Novartis Vaccines & Diagnostic expressão de antìgeno de superfìcie de vìrus da hepatite b para a preparação de vacina
LT2351578T (lt) 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ES2383209T3 (es) 2006-03-22 2012-06-19 Novartis Ag Regímenes para la inmunización con conjugados meningococicos
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
JP5637848B2 (ja) 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
FR2918671B1 (fr) * 2007-07-10 2010-10-15 Sanofi Pasteur Milieu de culture d'haemophilus influenzae type b.
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
TW201043267A (en) * 2009-03-19 2010-12-16 Intervet Int Bv In situ constituting a vaccine for administration to a predetermined herd of animals
PL2411048T3 (pl) * 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
RU2013136397A (ru) 2011-01-05 2015-02-10 Бхарат Байотек Интернэшнл Лимитед Комбинированная семивалентная вакцина
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
US9475848B2 (en) 2012-02-01 2016-10-25 Glaxosmithkline Biologicals S.A. Fermentation process for producing a virulence factor from bordetella
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CA2886938A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
WO2018156465A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
BR112020000999A2 (pt) 2017-07-18 2020-07-14 Serum Institute Of India Pvt Ltd. composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação
CA3115803A1 (en) 2018-10-12 2020-04-16 Serum Institute Of India Private Ltd. Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
WO2020236973A1 (en) 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
CN111658617A (zh) * 2019-10-14 2020-09-15 四川大学 一种含铝佐剂疫苗的冻干制剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
DE69113564T2 (de) * 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
AU685047B2 (en) 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
ES2126616T3 (es) * 1992-10-27 1999-04-01 American Cyanamid Co Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
IL122588A (en) * 1995-06-23 2001-12-23 Smithkline Beecham Biolog A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies

Also Published As

Publication number Publication date
JPH11507935A (ja) 1999-07-13
SI0833662T1 (en) 2001-12-31
IL122588A (en) 2001-12-23
EP0833662B1 (en) 2001-03-21
JP4850987B2 (ja) 2012-01-11
AU696338B2 (en) 1998-09-10
WO1997000697A1 (en) 1997-01-09
BG102146A (en) 1998-10-30
TW467746B (en) 2001-12-11
DE69612198T3 (de) 2011-08-18
HK1009764A1 (en) 1999-06-11
SI1082965T1 (sl) 2009-08-31
JP2008120833A (ja) 2008-05-29
CZ288908B6 (cs) 2001-09-12
MX9710521A (es) 1998-08-30
IL122588A0 (en) 1998-06-15
AU6359196A (en) 1997-01-22
PT833662E (pt) 2001-09-28
OA10646A (en) 2002-09-18
HU224514B1 (hu) 2005-10-28
CA2222455C (en) 2013-05-28
KR19990028336A (ko) 1999-04-15
MA23918A1 (fr) 1996-12-31
AP812A (en) 2000-02-24
ATE199831T1 (de) 2001-04-15
HK1037516A1 (en) 2002-02-15
CN1146444C (zh) 2004-04-21
EP1082965B1 (en) 2009-06-10
ATE433329T1 (de) 2009-06-15
CY2297B1 (en) 2003-07-04
AR003006A1 (es) 1998-05-27
NO325169B1 (no) 2008-02-11
PL184872B1 (pl) 2003-01-31
PT1082965E (pt) 2009-07-01
TR199701682T1 (xx) 1998-06-22
ES2325301T3 (es) 2009-09-01
SI0833662T2 (sl) 2011-06-30
BRPI9609414B8 (pt) 2021-05-25
NO976035L (no) 1998-02-16
BR9609414B1 (pt) 2013-11-19
DK1082965T3 (da) 2009-07-27
DE69612198D1 (de) 2001-04-26
DZ2055A1 (fr) 2002-10-20
EP0833662A1 (en) 1998-04-08
PL324242A1 (en) 1998-05-11
DE69612198T2 (de) 2001-11-08
HUP9900061A1 (hu) 1999-04-28
HUP9900061A3 (en) 2000-03-28
MY114786A (en) 2003-01-31
ES2157447T3 (es) 2001-08-16
DK0833662T3 (da) 2001-07-09
GR3036088T3 (en) 2001-09-28
DE69637950D1 (de) 2009-07-23
CN1188418A (zh) 1998-07-22
AP9701159A0 (en) 1998-01-31
NZ312132A (en) 1999-04-29
CZ418997A3 (cs) 1998-06-17
BR9609414A (pt) 1999-05-18
NO976035D0 (no) 1997-12-22
EG25924A (en) 2012-10-22
KR100425929B1 (ko) 2004-05-31
ES2157447T5 (es) 2011-04-29
PE11298A1 (es) 1998-03-20
SK176197A3 (en) 1998-07-08
EP1082965A1 (en) 2001-03-14
EP0833662B2 (en) 2011-01-26
BG62720B1 (bg) 2000-06-30
DK0833662T4 (da) 2011-02-28
CA2222455A1 (en) 1997-01-09

Similar Documents

Publication Publication Date Title
MY114786A (en) Vaccines
BR9608612A (pt) Vacina compreendendo um conjugado de antígeno de polissacarídeo - proteína portadora e proteína portadora livre
CY1105389T1 (el) Hpv-e7 ως αγωγη εναντι του ιου θηλωματων ανθρωπου
PT96330A (pt) Processo de preparacao de preparados contendo l-tartarato de l-carnitina
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
ZA872166B (en) Synthetic htlv-iii peptides,compositions and uses thereof
FR2603107B1 (fr) Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus
EA199900067A1 (ru) Очищенный поверхностный антиген сперматозоидов, моноклональное антитело для него и их применения
CA2169297A1 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
ID21338A (id) Metoda untuk menghasilkan kekebalan aktif dengan vaksin gabungan
BR0113155A (pt) Métodos para produção de uma vacina para hepatite b e de um antìgeno de superfìcie para hepatite b e para tratamento e/ou profilaxia de infeções pelo vìrus da hepatite b, composição de vacina, uso de um antìgeno de superfìcie para hepatite b, antìgeno imunogênico de hepatite b e vacina
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
BR9007702A (pt) Metodo de tratamento
ES2126616T3 (es) Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
RU93048161A (ru) Комбинированная педиатрическая вакцина с усиленной иммуногенностью каждого вакционного компонента
ATE398137T1 (de) Porphyromonas gingivalis antigene zur diagnose und behandlung von periodontitis
Suzuki et al. Inhibition by Lipopolysaccharide (Endotoxin) of Antibody Response of Rabbit to Common Antigen of Enterobacteriaceae.
DE69636527D1 (de) Antigenes protein aus malassezia
HUP9801917A2 (hu) Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
AU3868895A (en) Process for the preparation of furosemide
DE69322960D1 (de) Empfängnisverhütender impfstoff
RU96116250A (ru) Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
ATE204761T1 (de) Pharmazeutische antigen-/antikörperpräparation
EA200100107A1 (ru) Новые 2,3,3a,4,9,9a-гексагидро-8-гидрокси-1h-бенз[f]индолы, способ их получения и их применение в качестве лекарственных средств